The identification of infection takes too long, may not be precise, or is often too expensive. When you have an infection, your healthcare provider collects a sample to identify the infection. It is then transported to the laboratory which may require days enroute. During this time-period there is limited oversight or control of the sample. Time, environmental temperature, and transport media adversely affect the sample. When the sample arrives in the laboratory it usually requires additional days until the infection is identified. The impact of the current process is that results are delayed, falsely negative – especially when there are only a few bugs in the sample, falsely positive - especially when obtained weeks before needed, or may require expensive equipment and expertise to identify. This results in missed or delayed diagnosis and inadequate treatment.
Vax-Immune's LabReady® combines collection, protection, processing, transport, and enrichment of the sample and diagnosis of infection, and challenges established laboratory models. It is a proprietary, portable, disposable, hand-held device that strips out the loss of sample quality and time from collection to testing. Vax-Immune’s LabReady® is a unique platform technology that improves the diagnosis of infection by moving the laboratory to the patient. LabReady® makes diagnosing infection faster, simpler, easier, cheaper, and more accurate. It re-imagines the lab where everything happens before the sample arrives.
LabReady fits the current laboratory focused process of healthcare testing, but is also a gateway to the future. Next, LabReady will have Bluetooth and be equipped with a phone app. Each patient will then collect their sample with LabReady and LabReady will read and transmit the result to patient and healthcare provider. Imagine, diagnosing and treating infection without leaving your home.
There are too many babies with serious infections after birth that are preventable. These infections result in death (5% to 8%) and developmental disability (25% to 33%). Despite current screening for several of these bacteria during pregnancy, we continue to see mothers and babies with these infections. Why? Because if pregnant women were more accurately and quickly diagnosed prior to delivery, we could prevent the up to 80% of babies as well as mothers with group B streptococcus (GBS) infection that were missed. In addition, we could prevent other infections in mothers and babies.
JLABS provides us with several opportunities we could not have obtained elsewhere for each of our LabReady® products. 1) The facilities and equipment needed to conduct pre-clinical testing to validate each LabReady® product during the late design and early manufacturing phases. 2) The facilities and equipment to conduct FDA verification testing for each LabReady® product. 3) An environment conducive to and supportive to meeting advisers, investors, and collaborators. 4) J&J resources that have been wonderful in helping us address several manufacturing related questions. 5) The equipment and space to design and develop next generation versions of our LabReady® products. 6) The opportunity to learn from the many educational events conducted at JLABS. Finally, no one place could have provided all these opportunities in one location.
Meet the team:
President & CTO
Bhairavi Parikh PhD
Director of Product Development
William von Brendel MBA
Director of Business Development
Scott Miller BSE
Director of Manufacturing
Tom Renner BSE
Director of Quality Assurance